Covaxin gets nod for phase 2/3 trials on 2-18 year-olds: Why it is significant

The Subject Expert Committee (SEC) on COVID-19 has given a green signal to Bharat Biotech’s Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. This comes amid high cases of infection in children and teenagers in the second wave of Covid. Experts have also warned that a third wave could be more dangerous for children. Doctors have also said that it is important to vaccinate children as they can be super-spreaders. Watch this video for all the details.